Imunon, Inc. (IMNN)
NASDAQ: IMNN · Real-Time Price · USD
0.5251
-0.0985 (-15.80%)
At close: Jul 23, 2025, 4:00 PM
0.5400
+0.0149 (2.84%)
After-hours: Jul 23, 2025, 7:59 PM EDT
Imunon Revenue
Revenue (ttm)
n/a
Revenue Growth
n/a
P/S Ratio
n/a
Revenue / Employee
n/a
Employees
25
Market Cap
11.19M
Revenue Chart
Revenue History
Sources: Historical revenue is based on company filings submitted to the U.S. Securities and Exchange Commission (SEC). The most recent revenue numbers may be taken from company press releases.
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
Company Name | Revenue |
---|---|
UnitedHealth Group | 410.06B |
Johnson & Johnson | 90.63B |
Merck & Co. | 63.92B |
AbbVie | 57.37B |
Novartis AG | 55.19B |
AstraZeneca | 54.98B |
Eli Lilly and Company | 49.00B |
Novo Nordisk | 43.92B |
IMNN News
- 15 hours ago - IMUNON Announces Reverse Stock Split - GlobeNewsWire
- 8 days ago - IMUNON Granted Continued Listing Extension by Nasdaq to Complete Compliance Plan - GlobeNewsWire
- 5 weeks ago - IMUNON Presents Positive Phase 2 Translational Data of IMNN-001 in Advanced Ovarian Cancer at ESMO Gynaecological Cancers Congress 2025 - GlobeNewsWire
- 5 weeks ago - IMUNON Announces PlaCCine® DNA Vaccine Technology Abstract Selected for Oral Presentation at 10th International Conference on Vaccines Research & Development™ - GlobeNewsWire
- 7 weeks ago - IMUNON Announces Data Presented at ASCO Reinforces Unprecedented Overall Survival in Ovarian Cancer Phase 2 Study - GlobeNewsWire
- 7 weeks ago - IMUNON CEO RECAPS A YEAR OF CLINICAL ACHIEVEMENT AND SOLID FUNDAMENTALS - GlobeNewsWire
- 2 months ago - IMUNON Invited to Present Translational Data in Supporting Remarkable Phase 2 Ovarian Cancer Survival Results at ESMO Gynaecological Cancers Congress 2025 - GlobeNewsWire
- 2 months ago - IMUNON Announces Up To $9.75 Million Private Placement Priced At-The-Market Under Nasdaq Rules - GlobeNewsWire